Zynex (NASDAQ:ZYXI) Stock Rating Lowered by LADENBURG THALM/SH SH

Zynex (NASDAQ:ZYXI) was downgraded by research analysts at LADENBURG THALM/SH SH from a “buy” rating to a “neutral” rating in a report released on Wednesday, Marketbeat.com reports.

Separately, HC Wainwright reissued a “buy” rating and issued a $17.00 price target on shares of Zynex in a report on Friday, December 6th.

Zynex Stock Performance

ZYXI stock opened at $2.90 on Wednesday. Zynex has a twelve month low of $2.77 and a twelve month high of $13.19. The company has a quick ratio of 3.15, a current ratio of 3.94 and a debt-to-equity ratio of 1.66. The business’s fifty day simple moving average is $7.52 and its two-hundred day simple moving average is $7.95. The firm has a market cap of $92.35 million, a price-to-earnings ratio of 19.33 and a beta of 0.81.

Zynex (NASDAQ:ZYXI) last issued its quarterly earnings data on Tuesday, March 11th. The company reported ($0.02) earnings per share for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.11). Zynex had a net margin of 2.49% and a return on equity of 13.05%. The company had revenue of $45.98 million for the quarter, compared to the consensus estimate of $53.65 million. During the same period in the previous year, the business earned $0.04 EPS. Analysts predict that Zynex will post 0.2 earnings per share for the current year.

Insider Activity at Zynex

In other news, CFO Daniel J. Moorhead sold 10,000 shares of Zynex stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $7.88, for a total value of $78,800.00. Following the sale, the chief financial officer now directly owns 26,299 shares of the company’s stock, valued at $207,236.12. The trade was a 27.55 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Over the last ninety days, insiders sold 30,000 shares of company stock worth $227,100. 52.13% of the stock is owned by corporate insiders.

Institutional Trading of Zynex

A number of institutional investors have recently made changes to their positions in ZYXI. Hotchkis & Wiley Capital Management LLC boosted its stake in Zynex by 24.7% during the third quarter. Hotchkis & Wiley Capital Management LLC now owns 746,380 shares of the company’s stock worth $6,090,000 after buying an additional 147,770 shares during the last quarter. Geode Capital Management LLC boosted its stake in Zynex by 4.1% during the fourth quarter. Geode Capital Management LLC now owns 443,020 shares of the company’s stock worth $3,549,000 after buying an additional 17,511 shares during the last quarter. Royce & Associates LP boosted its stake in Zynex by 9.2% during the third quarter. Royce & Associates LP now owns 257,291 shares of the company’s stock worth $2,099,000 after buying an additional 21,781 shares during the last quarter. Janney Montgomery Scott LLC boosted its stake in Zynex by 10.3% during the fourth quarter. Janney Montgomery Scott LLC now owns 159,259 shares of the company’s stock worth $1,276,000 after buying an additional 14,820 shares during the last quarter. Finally, Renaissance Technologies LLC boosted its stake in Zynex by 2.8% during the fourth quarter. Renaissance Technologies LLC now owns 137,362 shares of the company’s stock worth $1,100,000 after buying an additional 3,800 shares during the last quarter. 29.68% of the stock is owned by institutional investors and hedge funds.

About Zynex

Zynex, Inc, together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device.